Clinical trial: Peg-interferon alfa-2b and ribavirin for the treatment of genotype-1 hepatitis C recurrence after liver transplantation

Alimentary Pharmacology and Therapeutics

Volumn 28, Issue 4, 2008, Pages 450-457

  Lodato, F ^a   Berardi, S ^a   Gramenzi, A ^a   Mazzella, G ^a   Lenzi, M ^a   Morelli, M C ^a   Tame, M R ^a   Piscaglia, F ^a   Andreone, P ^a   Ballardini, G ^a   Bernardi, M ^a   Bianchi, F B ^a   Biselli, M ^a   Bolondi, L ^a   Cescon, M ^a   Colecchia, A ^a   D'Errico, A ^a   Del Gaudio, M ^a   Ercolani, G ^a   Grazi, G L ^a   Grigioni, W ^a   Lorenzini, S ^a   Pinna, A D ^a   Ravaioli, M ^a   Roda, E ^a   Sama, C ^a   Vivarelli, M ^a   more..

^a UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; CYCLOSPORIN; ERYTHROPOIETIN; GRANULOCYTE COLONY STIMULATING FACTOR; PEGINTERFERON ALPHA2B; RECOMBINANT ERYTHROPOIETIN; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; RIBAVIRIN; STEROID; TACROLIMUS; VIRUS RNA;

ADULT; AGED; ANEMIA; ARTERY OCCLUSION; ARTICLE; ASTHENIA; AUTOIMMUNE DISEASE; AUTOIMMUNE GASTRITIS; AUTOIMMUNE GASTRITITS; AUTOIMMUNE HEPATITIS; AUTOIMMUNE HYPERTHYROIDISM; CLINICAL TRIAL; DECOMPENSATED LIVER CIRRHOSIS; DECREASED APPETITE; DEPRESSION; DRUG EFFICACY; DRUG SAFETY; EARLY VIROLOGICAL RESPONSE; FEMALE; FEVER; FLU LIKE SYNDROME; GASTRITIS; GENOTYPE; HEPATIC ARTERY; HEPATITIS C; HUMAN; HUMAN TISSUE; HYPERTHYROIDISM; INFECTION; LIVER ARTERY STENOSIS; LIVER FAILURE; LIVER TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; NEUTROPENIA; PREDICTION; PRIORITY JOURNAL; RAPID VIROLOGICAL RESPONSE; RECURRENT DISEASE; SIDE EFFECT; TREATMENT RESPONSE;

ADULT; AGED; ANTIVIRAL AGENTS; DRUG THERAPY, COMBINATION; FEMALE; GENOTYPE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; INTERFERON ALFA-2B; LIVER TRANSPLANTATION; MALE; MIDDLE AGED; PATIENT SELECTION; RECURRENCE; RIBAVIRIN; RNA, VIRAL; TREATMENT OUTCOME;

EID: 47749146522     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/j.1365-2036.2008.03761.x     Document Type: Article

References (33)

1. European Liver Transplant Registry (ELTR). Registry for the European Liver Transplant Association, Data Analysis. 05/1968-06/2003. Available at: http://www.eltr.org
2. Forman LM, Lewis JD, Berlin JA, Feldman HI, Lucey MR. The association between hepatitis C infection and survival after orthotopic liver transplantation. Gastroenterology 2002 122 : 889 96.
3. Gane EJ, Naoumov NV, Qian KP, et al. A longitudinal analysis of hepatitis C virus replication following liver transplantation. Gastroenterology 1996 110 : 167 77.
4. Berenguer M, Prieto M, Rayon JM, et al. Natural history of clinically compensated hepatitis C virus-related graft cirrhosis after liver transplantation. Hepatology 2000 32 : 852 8.
5. Berenguer M, Ferrell L, Watson J, et al. HCV-related fibrosis progression following liver transplantation: increase in recent years. J Hepatol 2000 32 : 673 84.
6. Ahmad J, Dodson SF, Demetris AJ, Fung JJ, Shakil AO. Recurrent hepatitis C after liver transplantation: a nonrandomized trial of interferon alfa alone versus interferon alfa and ribavirin. Liver Transpl 2001 7 : 863 9.
7. Firpi RJ, Abdelmalek MF, Soldevila-Pico C, et al. Combination of interferon alfa-2b and ribavirin in liver transplant recipients with histological recurrent hepatitis C. Liver Transpl 2002 8 : 1000 6.
8. Shakil AO, McGuire B, Crippin J, et al. A pilot study of interferon alfa and ribavirin combination in liver transplant recipients with recurrent hepatitis C. Hepatology 2002 36 : 1253 8.
9. Samuel D, Bizollon T, Feray C, et al. Interferon-alpha 2b plus ribavirin in patients with chronic hepatitis C after liver transplantation: a randomized study. Gastroenterology 2003 124 : 642 50.
10. Giostra E, Kullak-Ublick GA, Keller W, et al. Ribavirin/interferon-alpha sequential treatment of recurrent hepatitis C after liver transplantation. Transpl Int 2004 17 : 169 76.
11. Manns MP, McHutchison JG, Gordon SC, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001 358 : 958 65.
12. Fried MW, Shiffman ML, Reddy KR, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002 347 : 975 82.
13. Dumortier J, Scoazec JY, Chevallier P, Boillot O. Treatment of recurrent hepatitis C after liver transplantation: a pilot study of peginterferon alfa-2b and ribavirin combination. J Hepatol 2004 40 : 669 74.
14. Rodriguez-Luna H, Khatib A, Sharma P, et al. Treatment of recurrent hepatitis C infection after liver transplantation with combination of pegylated interferon alpha2b and ribavirin: an open-label series. Transplantation 2004 77 : 190 4.
15. Mukherjee S. Pegylated interferon alfa-2a and ribavirin for recurrent hepatitis C after liver transplantation. Transplant Proc 2005 37 : 4403 5.
16. Castells L, Vargas V, Allende H, et al. Combined treatment with pegylated interferon (alpha-2b) and ribavirin in the acute phase of hepatitis C virus recurrence after liver transplantation. J Hepatol 2005 43 : 53 9.
17. Neff GW, Montalbano M, O'Brien CB, et al. Treatment of established recurrent hepatitis C in liver-transplant recipients with pegylated interferon-alfa-2b and ribavirin therapy. Transplantation 2004 78 : 1303 7.
18. Angelico M, Petrolati A, Lionetti R, et al. A randomized study on Peg-interferon alfa-2a with or without ribavirin in liver transplant recipients with recurrent hepatitis C. J Hepatol 2007 46 : 1009 17.
19. Carrion JA, Navasa M, Garcia-Retortillo M, et al. Efficacy of antiviral therapy on hepatitis C recurrence after liver transplantation: a randomized controlled study. Gastroenterology 2007 132 : 1746 56.
20. Toniutto P, Fabris C, Fumo E, et al. Pegylated versus standard interferon-alpha in antiviral regimens for post-transplant recurrent hepatitis C: comparison of tolerability and efficacy. J Gastroenterol Hepatol 2005 20 : 577 82.
21. Kugelmas M, Osgood MJ, Trotter JF, et al. Hepatitis C virus therapy, hepatocyte drug metabolism, and risk for acute cellular rejection. Liver Transpl 2003 9 : 1159 65.
22. Dousset B, Conti F, Houssin D, Calmus Y. Acute vanishing bile duct syndrome after interferon therapy for recurrent HCV infection in liver-transplant recipients. N Engl J Med 1994 330 : 1160 1.
23. Cholongitas E, Samonakis D, Patch D, et al. Induction of autoimmune hepatitis by pegylated interferon in a liver transplant patient with recurrent hepatitis C virus. Transplantation 2006 81 : 488 90.
24. Berardi S, Lodato F, Gramenzi A, et al. High incidence of allograft dysfunction in liver transplant patients treated with Peg-interferon alfa-2b and ribavirin for hepatitis C recurrence: possible de novo autoimmune hepatitis? Gut 2007 56 : 237 42.
25. Kontorinis N, Agarwal K, Elhajj N, Fiel MI, Schiano TD. Pegylated interferon-induced immune-mediated hepatitis post-liver transplantation. Liver Transpl 2006 12 : 827 30.
26. Knodell RG, Ishak KG, Black WC, et al. Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis. Hepatology 1981 1 : 431 5.
27. Alvarez F, Berg PA, Bianchi FB, et al. International Autoimmune Hepatitis Group Report: review of criteria for diagnosis of autoimmune hepatitis. J Hepatol 1999 31 : 929 38.
28. Biselli M, Lorenzini S, Gramenzi A, et al. Hepatic artery stenosis in liver transplanted patients treated with pegylated interferon alpha-2b and ribavirin. Transplantation 2004 78 : 953.
29. Fabbri C, Jaboli MF, Giovanelli S, et al. Gastric autoimmune disorders in patients with chronic hepatitis C before, during and after interferon-alpha therapy. World J Gastroenterol 2003 9 : 1487 90.
30. Lodato F, Tame MR, Colecchia A, et al. Systemic lupus erythematosus following virological response to peginterferon alfa-2b in a transplanted patient with chronic hepatitis C recurrence. World J Gastroenterol 2006 12 : 4253 5.
31. Berenguer M, Palau A, Fernandez A, et al. Efficacy, predictors of response, and potential risks associated with antiviral therapy in liver transplant recipients with recurrent hepatitis C. Liver Transpl 2006 12 : 1067 76.
32. Picciotto FP, Tritto G, Lanza AG, et al. Sustained virological response to antiviral therapy reduces mortality in HCV reinfection after liver transplantation. J Hepatol 2007 46 : 459 65.
33. Sanchez-Tapias JM, Diago M, Escartin P, et al. Peginterferon-alfa2a plus ribavirin for 48 versus 72 weeks in patients with detectable hepatitis C virus RNA at week 4 of treatment. Gastroenterology 2006 131 : 451 60.